We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

5 hedge funds and large institutions have $346K invested in Chemomab Therapeutics in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.03% → 0.01% (-0.02%)

17% less funds holding

Funds holding: 6 → 5 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

55% less capital invested

Capital invested by funds: $763K → $346K (-$417K)

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$129K
2
VF
Virtu Financial
New York
+$85.1K
3
Citadel Advisors
Citadel Advisors
Florida
+$18.3K
4
Morgan Stanley
Morgan Stanley
New York
+$12.2K

Top Sellers

Rank Fund Capital Flow
1
PCM
Palisade Capital Management
New Jersey
-$421K
2
MIH
Meitav Investment House
Israel
-$267K
3
PF
Phoenix Financial
Israel
-$28K
4
Osaic Holdings
Osaic Holdings
Arizona
-$3K

CMMB Hedge Fund Activity: Q4 2020 in Review

5 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2020, worth a combined $346K — down 55% from $763K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CMMB and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $129K. The largest seller was Palisade Capital Management, exiting entirely with an estimated $421K sold.

  • 5 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2020, down from 6 in Q3 2020.
  • Funds reported $346K of Chemomab Therapeutics stock for Q4 2020, down 55% quarter-over-quarter.
  • 3 funds opened new Chemomab Therapeutics positions in Q4 2020 and 4 closed out, a net change of -1 holder.
  • The largest Chemomab Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $129K added.
  • The largest Chemomab Therapeutics seller in Q4 2020 was Palisade Capital Management, an estimated $421K sold.

Based on aggregated 13F filings for Q4 2020.